UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

23 Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Nov

21 Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Read More Share:

Nov

17 Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:

Nov

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Nov

11 United for Veterans and our Employees Who Serve

United for Veterans is one of UCB’s Employee Resource Groups (ERGs) focused on veterans and veteran supporters. United for Veterans leverages the combined strength of UCB’s veterans and veteran supporters by encouraging through shared experiences, celebrating veterans’ diversity, inspiring professional development, and honoring veteran communities through servant leadership opportunities while fulfilling our company goals and diversity, equity, and inclusion ambition.

Read More Share:

Nov

10 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:

Nov

09 Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Read More Share:

Nov

08 UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Read More Share:

Categories

Archives

Nov

23

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

21

Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

11

United for Veterans and our Employees Who Serve

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Nov

23

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

21

Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

11

United for Veterans and our Employees Who Serve

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact